# US 2022/0031749 A1 · Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031749 A1
- Document ID: US20220031749A1
- Status: Published application
- Kind: A1
- Application number: 17/309,408
- Filed: 2019-11-27
- Published: 2022-02-03
- Earliest claimed: 2018-11-28
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, The University of Texas System
- Inventors: Rafet Basar; Elizabeth Shpall; Katy Rezvani
- Web page: https://patentgrep.com/patent/US20220031749A1

## CPC

- C12N 5/0636: {T lymphocytes}
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/85: for animal cells
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2510/00: Genetically modified cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are methods for producing immune cells with disruption of multiple genes. Further provided are methods for inserting a chimeric antigen receptor at a gene locus of an immune cell.

## Claims

### Claim 1

An in vitro method for the disruption of at least two genes in an immune cell, wherein the at least two genes are selected from the group consisting of NKG2A, SIGLEC-7, LAG3, TIM3, CISH, FOXO1, TGFBR2, TIGIT, CD96, ADORA2, NR3C1, PD1, PDL-1, PDL-2, CD47, SIRPA, SHIP1, ADAM17, RPS6, 4EBP1, CD25, CD40, IL21R, ICAM1, CD95, CD80, CD86, IL10R, CD5, and CD7.

### Claim 2 (depends on 1)

The method of claim 1, wherein disruption comprises introducing a guide RNA (gRNA) for each gene to said immune cell.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the at least two genes are selected from the group consisting of (a) NKG2A and CISH, (b) NKG2A and TGFBRII, (c) CISH and TGFBRII, (d) TIGIT and FOXO1, (e) TIGIT and TGFBRII, (f) CD96 and FOXO1, (g) CD96 and TGFBRII, (h) FOXO1 and TGFBRII, (i) CD96 and TIGIT, (j) CISH and TIGIT, (k) TIM3 and CISH, (l) TIM3 and TGFBRII, (m) FOXO1 and TGFBRII, (n) TIM3 and TIGIT, (o) SIGLEC7 and CISH, (p) SIGLEC7 and TGFBRII, (q) CD47 and CISH, (r) CD47 and TGFBRII, (s) SIRPA and CISH, (t) SIRPA and TGFBRII, (u) CD47 and TIGIT, (v) CD47 and SIRPA, (w) A2AR and CISH, (x) A2AR and TGFBRII, (y) ADAM17 and CISH, (z) TGFBRII and ADAM17, (al) A2AR and TIGIT, (b1) SHP1 and CISH, (c1) CISH and TGFBRII, (d1) SHP1 and TGFBRII, (e1) SHP1 and TIGIT, and (f1) SHP1 and TIM3.

### Claim 4 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein at least 3 genes are disrupted.

### Claim 5 (depends on 4)

The method of claim 4, wherein the at least 3 genes are selected from the group consisting of (1) NKG2A, CISH, and TGFBRII, (2) TIGIT, FOXO1, and TGFBRII, (3) TGFBRII, CD96, and TIGIT, (4) TGFBR2, CISH, and TIGIT, (5) TIM3, CISH, and TGFBRII, (6) CD96, FOXO1, and TGFBRII, (7) TGFBRII, TIM3, and TIGIT, (8) SIGLEC7, CISH, and TGFBRII, (9) CD47, CISH, and TGFBRII, (10) SIRPA, CISH, and TGFBRII, (11) TGFBRII, CD47, and TIGIT, (12) TGFBRII, CD47, and SIRPA, (13) A2AR, CISH, and TGFBRII, (14) TGFBRII, CISH, and ADAM17, (15) TGFBRII, TIM3, and TIGIT, (16) TGFBRII, A2AR, and TIGIT, (17) SHP1, CISH, and TGFBRII, (18) TGFBRII, CISH, and SHP1, (19) TGFBRII, SHP1, and TIGIT, and (20) TGFBRII, SHP1, and TIM3.

### Claim 6 (depends on 2)

The method of claim 2, further comprising introducing an RNA-guide endonuclease.

### Claim 7 (depends on 6)

The method of claim 6, wherein the RNA-guided endonuclease is Cas9.

### Claim 8 (depends on 6)

The method of claim 6, wherein introducing the RNA-guided endonuclease comprises introducing a nucleic acid encoding the RNA-guided endonuclease into the immune cell.

### Claim 9 (depends on 8)

The method of claim 8, wherein the nucleic acid is mRNA.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any of claims 1-9, wherein three, four, five, or six genes are disrupted.

### Claim 11 (depends on 10)

The method of claim 10, wherein the genes comprise two of (a)-(j1) subgroups.

### Claim 12 (depends on 10)

The method of claim 10, wherein the genes comprise one subgroup of (a)-(j1) and one subgroup of 1-23.

### Claim 13 (depends on 10)

The method of claim 10, wherein the genes comprise two of 1-23 subgroups.

### Claim 14 (depends on 1)

The method of claim 1, wherein the disruption is simultaneous.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any of claims 1-14, wherein the immune cell is a T cell, NK cell, NK T cell, B cell, or stem cell.

### Claim 16 (depends on 15)

The method of claim 15, wherein the immune cell is engineered to express a chimeric antigen receptor (CAR) and/or T cell receptor (TCR).

### Claim 17 (depends on 15)

The method of claim 15, wherein the immune cell is engineered to express a CAR.

### Claim 18 (depends on 15)

The method of claim 15, wherein the immune cell is engineered to express a TCR.

### Claim 19 (depends on 15)

The method of claim 15, wherein the immune cell is engineered to express a CAR and TCR.

### Claim 20 (depends on 15)

The method of claim 15, wherein the immune cell is virus-specific.

### Claim 21 (depends on 15)

The method of claim 15, wherein the T cell is a virus-specific T cell.

### Claim 22 (depends on 15)

The method of claim 15, wherein the T cell is a regulatory T cell.

### Claim 23 (depends on 15)

The method of claim 15, wherein the B cell is a regulatory B cell.

### Claim 24 (depends on 15)

The method of claim 15, wherein the stem cell is a mesenchymal stem cell (MSC) or an induced pluripotent stem (iPS) cell.

### Claim 25 (depends on 15)

The method of claim 15, wherein the T cell is a CD8+ T cell, CD4+ T cell, gamma-delta T cell, or mixture thereof.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any of claims 1-25, wherein the immune cell is isolated from peripheral blood, cord blood, bone marrow or a mixture thereof.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26, wherein the immune cell is isolated from cord blood.

### Claim 28 (depends on 27)

The method of claim 27, wherein the cord blood is pooled from 2 or more individual cord blood units.

### Claim 29 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any of claims 2-28, wherein introducing comprises transfecting or transducing.

### Claim 30 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any of claims 2-28, wherein introducing comprises electroporation.

### Claim 31 (depends on 30)

The method of claim 30, wherein electroporation is performed more than once.

### Claim 32 (depends on 31)

The method of claim 31, wherein two rounds of electroporation are performed.

### Claim 33 (depends on 32)

The method of claim 32, wherein a first group of CRISPR gRNAs are introduced in a first electroporation and a second group of CRISPR gRNAs are introduced in a second round of electroporation.

### Claim 34 (depends on 33)

The method of claim 33, wherein the first group and/or second group of CRISPR gRNAs comprise 1, 2, 3, or 4 CRISPR gRNAs.

### Claim 35 (depends on 32)

The method of claim 32, wherein two CRISPR gRNAs are introduced in a first electroporation and two CRISPR gRNAs are introduced in a second round of electroporation.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 1-35, wherein the method comprises disrupting NKG2A, CD47, TGFβR2, and CISH.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 1-35, wherein the method comprises disrupting NKG2A, CISH, TGFβR2 and ADORA2.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 1-35, wherein the method comprises disrupting NKG2A, TGFβR2 and CISH.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 1-35, wherein the method comprises disrupting TIGIT, CD96, CISH, and ADORA2.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 1-35, wherein the method comprises disrupting ADAM17, TGFβR2 NKG2A and SHP1.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any of claims 1-40, wherein the disruption results in enhanced antitumor cytotoxicity, in vivo proliferation, in vivo persistence, and/or improved function of the immune cell.

### Claim 42 (depends on 41)

The method of claim 41, wherein the immune cell has increased secretion of IFN-γ, CD107, and/or TNFα.

### Claim 43 (depends on 41)

The method of claim 41, wherein the immune cell has increased production of perforin and/or granzyme B.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any of claims 1-43, further comprising introducing a CAR or TCR to said immune cell.

### Claim 45 (depends on 44)

The method of claim 44, wherein introducing comprises introducing a nucleic acid encoding said CAR or TCR into said immune cell.

### Claim 46 (depends on 45)

The method of claim 45, wherein the nucleic acid is in an expression vector.

### Claim 47 (depends on 46)

The method of claim 46, wherein the expression vector is a retroviral vector.

### Claim 48 (depends on 47)

The method of claim 47, wherein the retroviral vector is an adenovirus-associated vector.

### Claim 49 (depends on 48)

The method of claim 48, wherein the adenovirus-associated vector is AAV6.

### Claim 50 (depends on 46)

The method of claim 46, wherein the vector further comprises an inhibitory gene sequence.

### Claim 51 (depends on 50)

The method of claim 50, wherein the inhibitory gene sequence is selected from the group consisting of NKG2A, SIGLEC-7, LAG3, TIM3, CISH, FOXO1, TGFBR2, TIGIT, CD96, ADORA2, NR3C1, PD1, PDL-1, PDL-2, CD47, SIRPA, SHIP1, ADAM17, RPS6, 4EBP1, CD25, CD40, IL21R, ICAM1, CD95, CD80, CD86, IL10R, CD5, and CD7.

### Claim 52 (depends on 50)

The method of claim 50, wherein the vector further comprises a guide RNA for said inhibitory gene.

### Claim 53 (depends on 52)

The method of claim 52, wherein the CAR is flanked by homology arms for said inhibitory gene.

### Claim 54 (depends on 53)

The method of claim 53, wherein introducing the vector comprising the CAR sequence results in insertion of the CAR at the inhibitory gene locus in said immune cell.

### Claim 55 (depends on 54)

The method of claim 54, wherein the CAR is inserted at an exon of said inhibitory gene.

### Claim 56 (depends on 54)

The method of claim 54, wherein the CAR is under the control of the endogenous promoter of the inhibitory gene.

### Claim 57 (depends on 54)

The method of claim 54, wherein introducing the vector further disrupts expression of said inhibitory gene.

### Claim 58

An immune cell with disrupted expression of at least two genes in the immune cell, wherein the at least two genes are selected from the group consisting of NKG2A, SIGLEC-7, LAG3, TIM3, CISH, FOXO1, TGFBR2, TIGIT, CD96, ADORA2, NR3C1, PD1, PDL-1, PDL-2, CD47, SIRPA, SHIP1, ADAM17, RPS6, 4EBP1, CD25, CD40, IL21R, ICAM1, CD95, CD80, CD86, IL10R, CD5, and CD7.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The cell of claim 58, wherein the cell is produced according to any one of claims 1-57.

### Claim 60 (depends on 58)

The cell of claim 58, wherein three, four, five, or six genes are disrupted.

### Claim 61 (depends on 58)

The cell of claim 58, wherein the immune cell is a T cell, NK cell, NK T cell, B cell, or stem cell.

### Claim 62 (depends on 58)

The cell of claim 58, wherein the immune cell is engineered to express a chimeric antigen receptor (CAR) and/or T cell receptor (TCR).

### Claim 63 (depends on 58)

The cell of claim 58, wherein the immune cell is engineered to express a CAR.

### Claim 64 (depends on 58)

The cell of claim 58, wherein the immune cell is engineered to express a TCR.

### Claim 65 (depends on 58)

The cell of claim 58, wherein the immune cell is engineered to express a CAR and TCR.

### Claim 66 (depends on 58)

The cell of claim 58, wherein the immune cell is virus-specific.

### Claim 67 (depends on 61)

The cell of claim 61, wherein the T cell is a virus-specific T cell.

### Claim 68 (depends on 61)

The cell of claim 61, wherein the T cell is a regulatory T cell.

### Claim 69 (depends on 61)

The cell of claim 61, wherein the B cell is a regulatory B cell.

### Claim 70 (depends on 61)

The cell of claim 61, wherein the stem cell is a mesenchymal stem cell (MSC) or an induced pluripotent stem (iPS) cell.

### Claim 71 (depends on 61)

The cell of claim 61, wherein the T cell is a CD8+ T cell, CD4+ T cell, or gamma-delta T cell.

### Claim 72 (depends on 58)

The cell of claim 58, wherein the immune cell is isolated from peripheral blood, cord blood, bone marrow, or a mixture thereof.

### Claim 73 (depends on 58)

The cell of claim 58, wherein the immune cell is isolated from cord blood.

### Claim 74 (depends on 73)

The cell of claim 73, wherein the cord blood is pooled from 2 or more individual cord blood units.

### Claim 75 (depends on 58)

The cell of claim 58, wherein the immune cell has disrupted NKG2A, CD47, TGFβR2, and CISH.

### Claim 76 (depends on 58)

The cell of claim 58, wherein the immune cell has disrupted NKG2A, CISH, TGFβR2 and ADORA2.

### Claim 77 (depends on 58)

The cell of claim 58, wherein the immune cell has disrupted NKG2A, TGFβR2 and CISH.

### Claim 78 (depends on 58)

The cell of claim 58, wherein the immune cell has disrupted TIGIT, CD96, CISH, and ADORA2.

### Claim 79 (depends on 58)

The cell of claim 58, wherein the immune cell has disrupted ADAM17, TGFβR2 NKG2A and SHP1.

### Claim 80 (depends on 58)

The cell of claim 58, wherein the immune cell has enhanced antitumor cytotoxicity, in vivo proliferation, in vivo persistence, and/or improved function.

### Claim 81 (depends on 58)

The cell of claim 58, wherein the immune cell has increased secretion of IFN-γ, CD107, and/or TNFα.

### Claim 82 (depends on 58)

The cell of claim 58, wherein the immune cell has increased production of perforin and/or granzyme B.

### Claim 83 (depends on 58)

The cell of claim 58, wherein the cell is engineered to express a CAR and/or TCR.

### Claim 84 (depends on 83)

The cell of claim 83, wherein the CAR is inserted at an endogenous inhibitory gene locus of said cell.

### Claim 85 (depends on 84)

The cell of claim 84, wherein the inhibitory gene locus is selected from the group consisting of NKG2A, SIGLEC-7, LAG3, TIM3, CISH, FOXO1, TGFBR2, TIGIT, CD96, ADORA2, NR3C1, PD1, PDL-1, PDL-2, CD47, SIRPA, SHIP1, ADAM17, RPS6, 4EBP1, CD25, CD40, IL21R, ICAM1, CD95, CD80, CD86, IL10R, CD5, and CD7.

### Claim 86 (depends on 84)

The cell of claim 84, wherein the CAR is under the control of the endogenous promoter of said inhibitory gene.

### Claim 87 (depends on 84)

The cell of claim 84, wherein the CAR was inserted at the inhibitory gene locus by CRISPR-mediated gene editing.

### Claim 88 (depends on 83, 84, 85, 86, 87)

The cell of any one of claims 83-87, wherein the CAR comprises an antigen-binding domain selected from the group consisting of F(ab′)2, Fab′, Fab, Fv, and scFv.

### Claim 89 (depends on 83, 84, 85, 86, 87, 88)

The cell of any one of claims 83-88, wherein the CAR targets one or more tumor associated antigens selected from the group consisting of CD19, CD319 (CS1), ROR1, CD20, carcinoembryonic antigen, alphafetoprotein, CA-125, MUC-1, epithelial tumor antigen, melanoma-associated antigen, mutated p53, mutated ras, HER2/Neu, ERBB2, folate binding protein, HIV-1 envelope glycoprotein gp120, HIV-1 envelope glycoprotein gp41, GD2, CD5, CD123, CD23, CD30, CD56, c-Met, mesothelin, GD3, HERV-K, IL-11Ralpha, kappa chain, lambda chain, CSPG4, ERBB2, WT-1, TRAIL/DR4, VEGFR2, CD33, CD47, CLL-1, U5snRNP200, CD200, BAFF-R, BCMA, and CD99.

### Claim 90 (depends on 83, 84, 85, 86, 87, 88, 89, 90)

The cell of any one of claims 83-90, wherein the CAR comprises at least one signaling domain selected from the group consisting of CD3, CD28, OX40/CD134, 4-1BB/CD137, FcεRIγ, ICOS/CD278, ILRB/CD122, IL-2RG/CD132, DAP12, CD70, and CD40.

### Claim 91 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

The cell of any one of claims 58-90, wherein the cell is engineered to express a heterologous cytokine selected from the group consisting of IL-7, IL-2, IL-15, IL-12, IL-18, IL-21, and a combination thereof.

### Claim 92 (depends on 83)

The cell of claim 83, wherein the cell further comprises a suicide gene.

### Claim 93 (depends on 92)

The cell of claim 92, wherein the suicide gene is a membrane bound tumor necrosis factor (TNF)-alpha mutant gene.

### Claim 94

An expression vector encoding a CAR, inhibitory gene sequence, and gRNA.

### Claim 95 (depends on 94)

The vector of claim 94, wherein the inhibitory gene sequence is from an inhibitory gene selected from the group consisting of NKG2A, SIGLEC-7, LAG3, TIM3, CISH, FOXO1, TGFBR2, TIGIT, CD96, ADORA2, NR3C1, PD1, PDL-1, PDL-2, CD47, SIRPA, SHIP1, ADAM17, RPS6, 4EBP1, CD25, CD40, IL21R, ICAM1, CD95, CD80, CD86, IL10R, CD5, and CD7.

### Claim 96 (depends on 94)

The vector of claim 94, wherein the gRNA is specific to said inhibitory gene.

### Claim 97 (depends on 94)

The vector of claim 94, wherein the vector is a retroviral vector.

### Claim 98 (depends on 94)

The vector of claim 94, wherein the retroviral vector is an AAV vector.

### Claim 99 (depends on 94)

The vector of claim 94, wherein the CAR is flanked by homology arms for the inhibitory gene.

### Claim 100 (depends on 94, 95, 96, 97, 98, 99)

A host cell engineered to express the vector of any of claims 94-99.

### Claim 101 (depends on 100)

The cell of claim 100, wherein the cell is a T cell, NK cell, B cell, or stem cell.

### Claim 102 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 100)

The cell of claim 100, wherein the cell is a cell of any one of claims 58-83.

### Claim 103 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

A pharmaceutical composition comprising a population of immune cells of any one of claims 58-93.

### Claim 104 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

A composition comprising a population of cells of any one of claims 58-93 for the treatment of an immune-related disorder, infectious disease, or cancer.

### Claim 105 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

A method of treating a disease or disorder in a subject comprising administering an effective amount of immune cells of any one of claims 58-93 to the subject.

### Claim 106 (depends on 105)

The method of claim 105, wherein the disease or disorder is an infectious disease, cancer, or immune-related disorder.

### Claim 107 (depends on 106)

The method of claim 106, wherein the immune-related disorder is an autoimmune disorder, graft versus host disease, allograft rejection, or inflammatory condition.

### Claim 108 (depends on 106)

The method of claim 106, wherein the immune-related disorder is an inflammatory condition and the immune cells have essentially no expression of glucocorticoid receptor.

### Claim 109 (depends on 105, 106, 107, 108)

The method of any one of claims 105-108, wherein the immune cells are autologous to the subject.

### Claim 110 (depends on 105, 106, 107, 108)

The method of any one of claims 105-108, wherein the immune cells are allogeneic to the subject.

### Claim 111 (depends on 106)

The method of claim 106, wherein the immune-related disorder is a cancer.

### Claim 112 (depends on 111)

The method of claim 111, wherein the cancer is a solid cancer or a hematologic malignancy.

### Claim 113 (depends on 105, 106, 107, 108, 109, 110, 111, 112)

The method of any one of claims 105-112, further comprising administering to the subject at least a second therapeutic agent.

### Claim 114 (depends on 113)

The method of claim 113, wherein the at least a second therapeutic agent comprises chemotherapy, immunotherapy, surgery, radiotherapy, or biotherapy.

### Claim 115 (depends on 113, 114)

The method of claim 113 or 114, wherein the immune cells and/or the at least a second therapeutic agent are administered intravenously, intraperitoneally, intratracheally, intratumorally, intramuscularly, endoscopically, intralesionally, percutaneously, subcutaneously, regionally, or by direct injection or perfusion.

### Claim 116

A method for engineering an immune cell to express a CAR, said method comprising using a CRISPR gRNA to insert the CAR at an inhibitory gene locus of said immune cell.

### Claim 117 (depends on 116)

The method of claim 116, wherein the CAR is encoded by an expression vector.

### Claim 118 (depends on 117)

The method of claim 117, wherein the expression vector is a retroviral vector.

### Claim 119 (depends on 118)

The method of claim 118, wherein the retroviral vector is an adenovirus-associated vector.

### Claim 120 (depends on 119)

The method of claim 119, wherein the adenovirus-associated vector is AAV6.

### Claim 121 (depends on 117)

The method of claim 117, wherein the vector further comprises an inhibitory gene sequence.

### Claim 122 (depends on 121)

The method of claim 121, wherein the inhibitory gene sequence is from an inhibitory gene selected from the group consisting of NKG2A, SIGLEC-7, LAG3, TIM3, CISH, FOXO1, TGFBR2, TIGIT, CD96, ADORA2, NR3C1, PD1, PDL-1, PDL-2, CD47, SIRPA, SHIP1, ADAM17, RPS6, 4EBP1, CD25, CD40, IL21R, ICAM1, CD95, CD80, CD86, IL10R, CD5, and CD7.

### Claim 123 (depends on 116, 117, 118, 119, 120, 121, 122)

The method of any one of claims 116-122, wherein the CRISPR gRNA is to said inhibitory gene.

### Claim 124 (depends on 116, 117, 118, 119, 120, 121, 122, 123)

The method of any one of claims 116-123, wherein the CAR is flanked by homology arms for said inhibitory gene.

### Claim 125 (depends on 116, 117, 118, 119, 120, 121, 122, 123, 124)

The method of any one of claims 116-124, wherein the CAR is inserted at an exon of said inhibitory gene.

### Claim 126 (depends on 116, 117, 118, 119, 120, 121, 122, 123, 124, 125)

The method of any one of claims 116-125, wherein the CAR is under the control of the endogenous promoter of the inhibitory gene.

### Claim 127 (depends on 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126)

The method of any one of claims 116-126, wherein the CAR disrupts the expression of said inhibitory gene.

### Claim 128 (depends on 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127)

The method of any one of claims 116-127, wherein the CAR targets one or more tumor associated antigens selected from the group consisting of CD19, CD319 (CS1), ROR1, CD20, carcinoembryonic antigen, alphafetoprotein, CA-125, MUC-1, epithelial tumor antigen, melanoma-associated antigen, mutated p53, mutated ras, HER2/Neu, ERBB2, folate binding protein, HIV-1 envelope glycoprotein gp120, HIV-1 envelope glycoprotein gp41, GD2, CD5, CD123, CD23, CD30, CD56, c-Met, mesothelin, GD3, HERV-K, IL-11Ralpha, kappa chain, lambda chain, CSPG4, ERBB2, WT-1, TRAIL/DR4, VEGFR2, CD33, CD47, CLL-1, U5snRNP200, CD200, BAFF-R, BCMA, and CD99.

### Claim 129 (depends on 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128)

The method of any one of claims 116-128, wherein the CAR comprises at least one signaling domain selected from the group consisting of CD3, CD28, OX40/CD134, 4-1BB/CD137, FcεRIγ, ICOS/CD278, ILRB/CD122, IL-2RG/CD132, DAP12, CD70, CD40, and a combination thereof.

### Claim 130 (depends on 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129)

The method of any one of claims 116-129, wherein the cell is engineered to express at least one heterologous cytokine selected from the group consisting of IL-7, IL-2, IL-15, IL-12, IL-18, IL-21, and a combination thereof.

### Claim 131 (depends on 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130)

The method of any one of claims 116-130, wherein the cell further comprises a suicide gene.

### Claim 132 (depends on 131)

The method of claim 131, wherein the suicide gene is a membrane bound tumor necrosis factor (TNF)-alpha mutant gene.

### Claim 133

An immune cell with a CAR inserted at an inhibitory gene of said immune cell.

### Claim 134 (depends on 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133)

The immune cell of claim 133, wherein the cell is produced by the method of any one of claims 116-132.

### Claim 135 (depends on 133, 134)

A composition comprising a population of immune cells of claim 133 or 134.

### Claim 136 (depends on 135)

The composition of claim 135, wherein the immune cell is a T cell, B cell, or NK cell.

### Claim 137 (depends on 133, 134, 135, 136)

A composition comprising a population of cells of any one of claims 133-136 for the treatment of an immune-related disorder, infectious disease, or cancer.

### Claim 138 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 100)

A method of treating a disease or disorder in a subject comprising administering an effective amount of cells of any one of claim 58-93, 100, or 133-134 to the subject.

### Claim 139 (depends on 138)

The method of claim 138, wherein the disease or disorder is an infectious disease, cancer or immune-related disorder.

### Claim 140 (depends on 139)

The method of claim 139, wherein the immune-related disorder is a autoimmune disorder, graft versus host disease, allograft rejection, or inflammatory condition.

### Claim 141 (depends on 139)

The method of claim 139, wherein the immune-related disorder is an inflammatory condition and the immune cells have essentially no expression of glucocorticoid receptor.

### Claim 142 (depends on 138, 139, 140, 141)

The method of any one of claims 138-141, wherein the cells are autologous for the subject.

### Claim 143 (depends on 138, 139, 140, 141)

The method of any one of claims 138-141, wherein the cells are allogeneic.

### Claim 144 (depends on 138)

The method of claim 138, wherein the immune-related disorder is a cancer.

### Claim 145 (depends on 144)

The method of claim 144, wherein the cancer is a solid cancer or a hematologic malignancy.

### Claim 146 (depends on 138, 139, 140, 141, 142, 143, 144, 145)

The method of any one of claims 138-145, further comprising administering to the subject at least a second therapeutic agent.

### Claim 147 (depends on 146)

The method of claim 146, wherein the at least a second therapeutic agent comprises chemotherapy, immunotherapy, surgery, radiotherapy, or biotherapy.

### Claim 148 (depends on 146, 147)

The method of claim 146 or 147, wherein the immune cells and/or the at least a second therapeutic agent are administered intravenously, intraperitoneally, intratracheally, intratumorally, intramuscularly, endoscopically, intralesionally, percutaneously, subcutaneously, regionally, or by direct injection or perfusion.
